Piet Wigerinck
Director/Board Member presso IPSEN
Patrimonio netto: 81 004 $ in data 31/03/2024
Profilo
Attualmente, Piet Wigerinck è direttore scientifico di Galapagos NV. È anche nel consiglio di amministrazione di Ipsen SA e Ipsen Pharma SAS. In passato è stato vicepresidente di Drug Discovery & Early Development presso Tibotec Pharmaceuticals e vicepresidente di Drug Discovery & Development Solutions Ltd. Il Dr. Wigerinck ha ricevuto un dottorato dalla Katholieke Universiteit Leuven.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
IPSEN SA
0.00% | 31/12/2022 | 680 ( 0.00% ) | 81 004 $ | 31/03/2024 |
Posizioni attive di Piet Wigerinck
| Società | Posizione | Inizio |
|---|---|---|
| IPSEN | Director/Board Member | 01/05/2018 |
University Hospital Antwerp
 University Hospital Antwerp Hospital/Nursing ManagementHealth Services University Hospital Antwerp provides clinical, patient care, academic training and scientific research services. The company was is headquartered in Belgium. | Director/Board Member | - |
miDIAGNOSTICS NV
 miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Director/Board Member | - |
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Director/Board Member | - |
| UZA Foundation | Director/Board Member | - |
Precedenti posizioni note di Piet Wigerinck
| Società | Posizione | Fine |
|---|---|---|
| GALAPAGOS NV | Chief Tech/Sci/R&D Officer | 31/12/2021 |
Xinvento BV
 Xinvento BV BiotechnologyHealth Technology Part of Rhythm Pharmaceuticals, Inc., Xinvento BV is a Dutch biotech company that develops therapies for congenital hyperinsulinism. The private company is based in Amsterdam, Netherlands. The company was founded in 2021 by Claudine van der Sande, Sarah Hafith-de Boer, Piet Wigerinck. Claudine van der Sande has been the CEO since 2021. Xinvento was acquired by Rhythm Pharmaceuticals Netherlands BV on February 27, 2023 for $222.43 million. | Founder | - |
| Tibotec-Virco Comm Va | Corporate Officer/Principal | - |
Drug Discovery & Development Solutions Ltd.
 Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Drug Discovery & Development Solutions Ltd. engages in the provision of financial services. The company is headquartered in Singapore. | Corporate Officer/Principal | - |
Formazione di Piet Wigerinck
| Katholieke Universiteit Leuven | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| IPSEN | Health Technology |
| GALAPAGOS NV | Health Technology |
| Aziende private | 7 |
|---|---|
University Hospital Antwerp
University Hospital Antwerp Hospital/Nursing ManagementHealth Services University Hospital Antwerp provides clinical, patient care, academic training and scientific research services. The company was is headquartered in Belgium. | Health Services |
miDIAGNOSTICS NV
miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Commercial Services |
Drug Discovery & Development Solutions Ltd.
Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Drug Discovery & Development Solutions Ltd. engages in the provision of financial services. The company is headquartered in Singapore. | Commercial Services |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
| Tibotec-Virco Comm Va | |
Xinvento BV
Xinvento BV BiotechnologyHealth Technology Part of Rhythm Pharmaceuticals, Inc., Xinvento BV is a Dutch biotech company that develops therapies for congenital hyperinsulinism. The private company is based in Amsterdam, Netherlands. The company was founded in 2021 by Claudine van der Sande, Sarah Hafith-de Boer, Piet Wigerinck. Claudine van der Sande has been the CEO since 2021. Xinvento was acquired by Rhythm Pharmaceuticals Netherlands BV on February 27, 2023 for $222.43 million. | Health Technology |
| UZA Foundation |
- Borsa valori
- Insiders
- Piet Wigerinck
